Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Formerly ASP7266, Verekitug
UPB-101 · 5 trials · 4 indications
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
An asthma exacerbation is defined as a worsening of asthma that required treatment with systemic (oral or intravenous) corticosteroids for at least three consecutive days or a single depo-injectable dose of corticosteroids or an emergency room (ER) or urgent care visit that required systemic corticosteroids or an admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for greater than or equal to 24 hours.
NPS is a physician-reported scoring system to estimate the extent or severity of nasal polyps (NPs) based on assessments by nasal endoscopy. Each nostril is scored on a categorical scale of 0 to 4 with a lower score indicating smaller-sized nasal polyps. The total score is the sum of the right and left scores (0-8). A higher score means more severe disease.
Overall Summary of Treatment-emergent Adverse Events (TEAEs) and Adverse Events (AEs) up to Week 24 (Safety Population)
| Arm | Type | Description |
|---|---|---|
| Verekitug (UPB-101) 100 mg and Placebo | EXPERIMENTAL | Participants will receive 0.5 milliliter (mL) of the formulated solution (containing 100 milligrams \[mg\] of verekitug \[UPB-101\]) and 2.0 mL of matching placebo subcutaneously in two separate injections every 12 weeks up to Week 96. |
| Verekitug (UPB-101) 400 mg and Placebo | EXPERIMENTAL | Participants will receive 2.0 mL of the formulated solution (containing 400 mg of verekitug \[UPB-101\]) and 0.5 mL of matching placebo subcutaneously in two separate injections every 24 weeks up to Week 96. Participants will also receive 2.0 mL and 0.5 mL of matching placebo subcutaneously in two separate injections at Weeks 12, 36, 60 and 84 visits. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive 0.5 mL of matching placebo and 2.0 mL of matching placebo subcutaneously in two separate injections every 12 weeks up to Week 96. |
| Verekitug 100 mg Q12W and Placebo | EXPERIMENTAL | Participants will receive 0.5 mL of verekitug (100 mg) and 2.0 mL of matching placebo, subcutaneous (SC) injections, every 12 weeks (Q12W) for up to 48 weeks. |
| Verekitug 400 mg Q24W and Placebo | EXPERIMENTAL | Participants will receive 2.0 mL of verekitug (400 mg) and 0.5 mL of matching placebo, SC injections, at Weeks 24 and 48 visits. Participants will also receive 2.0 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits. |
| Verekitug (UPB-101): 100 mg Q12W / Placebo | EXPERIMENTAL | Participants will receive 0.5 milliliter (mL) of verekitug (UPB-101) formulated solution (containing 100 milligrams \[mg\] of verekitug \[UPB-101\]) and 2.0 mL of placebo subcutaneously in two separate injections every 12 weeks up to Week 48. |
| Verekitug (UPB-101): 400 mg Q24W / Placebo | EXPERIMENTAL | Participants will receive 2.0 mL of verekitug (UPB-101) formulated solution (containing 400 mg of verekitug \[UPB-101\]) and 0.5 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits. |
| Verekitug (UPB-101): 100 mg Q24W / Placebo | EXPERIMENTAL | Participants will receive 0.5 mL of verekitug (UPB-101) formulated solution (containing 100 mg of verekitug \[UPB-101\]) and 2.0 mL of placebo subcutaneously in two separate injections every 24 weeks up to Week 48. Participants will also receive 2 mL and 0.5 mL of placebo subcutaneously in two separate injections at Weeks 12 and 36 visits. |
| Verekitug (UPB-101) | EXPERIMENTAL | Participants will be administered 0.5 milliliter (mL) of verekitug (UPB-101) formulated solution (containing 100 milligrams \[mg\] of verekitug \[UPB-101\]) subcutaneously, every 12 weeks for 24 weeks. |
| Matching placebo | PLACEBO_COMPARATOR | Participants will be administered verekitug (UPB-101) matching placebo solution, subcutaneously, every 12 weeks for 24 weeks. |
| Active substance 1 | EXPERIMENTAL | UPB-101 Cohort 1 |
| Active substance 2 | EXPERIMENTAL | UPB-101 Cohort 2 |
| Active substance 3 | EXPERIMENTAL | UPB-101 Cohort 3 |
| Active Substance 4 | EXPERIMENTAL | UPB-101 Cohort 4 |
| Name | Type | Description |
|---|---|---|
| Verekitug | DRUG | Verekitug (UPB-101) formulated solution |
| Placebo | OTHER | Matching Placebo to Verekitug (UPB-101) |
| Verekitug (UPB-101) | DRUG | Verekitug (UPB-101) formulated solution |
| UPB-101 | DRUG | Subcutaneous injection |
Inclusion Criteria: * Physician diagnosis of COPD for \>12 months. * Current or former smokers with a smoking history of 10 pack-years or more. * Post-bronchodilator FEV1/ Forced Vital Capacity (FVC) ratio \<0.70 and predicted post-bronchodilator FEV1 \>30% and ≤80%. * Modified Medical Research Cou...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
UPB-101 is an investigational small molecule being developed by Upstream Bio, Inc. for the treatment of asthma, a respiratory condition. It is in Phase 1 clinical development and has been studied in a completed early-stage trial. It is not an approved therapy.
UPB-101 is being studied as a treatment for asthma. Its only recorded clinical trial enrolled 32 adults with asthma in the United Kingdom to evaluate safety and biologic impact after repeated injections at increasing amounts. The drug remains investigational and is not approved for asthma or any other indication.
UPB-101 is developed by Upstream Bio, Inc., which trades under the ticker UPB. The company is the sponsor of the Phase 1 asthma program for this small molecule candidate.
UPB-101 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The program has tested the drug in 32 enrolled participants, all adults with asthma, in a randomized, double-blind, controlled study.
UPB-101 has been evaluated in one completed Phase 1 trial, NCT05448651, titled Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics. The trial enrolled 32 adults with asthma in the United Kingdom and used a randomized, double-blind, controlled design with biomarker selection.